Are you Dr. Malek?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Connect with colleagues in the same hospital or clinic
You already have 43 invites waiting! - Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
225 Quincy Ave
Brockton, MA 02302Phone+1 508-586-1410- Is this information wrong?
Summary
- Dr. Karim Malek, MD is an oncologist in Brockton, Massachusetts. He is currently licensed to practice medicine in Massachusetts. He is affiliated with Signature Healthcare Brockton Hospital and is an Assistant Clinical Professor at Tufts Medical Center.
Education & Training
Boston University Medical CenterResidency, Internal Medicine, 1999 - 2002- Boston University Medical CenterFellowship, Hematology and Medical Oncology, 1996 - 1999
University of Alexandria Faculty of MedicineClass of 1988
Certifications & Licensure
MA State Medical License 1999 - 2026- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- 75 citationsPhase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with pl...David M. O'Malley, Ursula A. Matulonis, Michael J. Birrer, Cesar M. Castro, Lucy Gilbert, Ignace Vergote, Lainie P. Martin, Gina Mantia-Smaldone, Antonio Gonzalez Mart...> ;Gynecologic Oncology. 2020 Feb 18
- 32 citationsEvaluation of Prophylactic Corticosteroid Eye Drop Use in the Management of Corneal Abnormalities Induced by the Antibody–Drug Conjugate Mirvetuximab SoravtansineUrsula A. Matulonis, Michael J. Birrer, David M. O'Malley, Kathleen N. Moore, Jason A. Konner, Lucy Gilbert, Lainie P. Martin, Todd M. Bauer, Amit M. Oza, Karim Malek,...> ;Clinical Cancer Research. 2019 Mar 15
- 48 citationsSafety and activity findings from a phase 1b escalation study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in c...Kathleen N. Moore, David M. O'Malley, Ignace Vergote, Lainie P. Martin, Antonio González-Martín, Karim Malek, Michael J. Birrer> ;Gynecologic Oncology. 2018 Oct 1
- Join now to see all
Press Mentions
Intellisee AI Risk Mitigation Platform Announces Product Launch: New Company Offers “Smarter Surveillance for a Safer World”September 14th, 2020
Professional Memberships
- Member
Hospital Affiliations
Signature Healthcare Brockton HospitalBrockton, Massachusetts
